Is Continuous Glucose Monitoring Underappreciated in the UK?
Abstract
Overview
I ntroduction: Information about continuous glucose monitoring (CGM) use in the UK is limited. We conducted an online survey of a
representative sample of current CGM users in England, Scotland and Wales to address this deficit. Methods: The 29-item online survey
was conducted between 29 December 2016 and 25 January 2017. Persons with type 1 diabetes (T1D) and caregivers of T1D children/
adolescents were recruited from mailing lists, using Nielsen and Harris Polling databases. Results: 315 patients and caregivers responded to
the survey – 170 adult patients and 145 caregivers. Among respondents, 144 received full funding for CGM use, 72 received partial funding
and 83 received no funding. Most reported improvements in glycated haemoglobin (HbA1c) (67.0%), fewer hypoglycaemia episodes (70.2%),
improved hypoglycaemia awareness (77.5%) and better diabetes management (92.4%). Self-funders reported significantly higher CGM use
(76.1%) than those who were fully funded (58.9%) and/or partially funded (65.9%), p=0.0008. Fewer than 50% of all respondents reported
receiving guidance in interpreting CGM data from their diabetes care team; 30.1% of self-funders reported receiving no CGM support from
their diabetes team compared with fully funded (2.8%) and partially funded (1.4%) respondents, p<0.0001. Conclusions: Patients with T1D
and their caregivers are realising benefits from CGM use but are largely unsupported by the UK healthcare system.
Keywords
Continuous glucose monitoring
(CGM), insulin, multiple daily insulin
injections (MDI), type 1 diabetes, selfmonitoring
of blood glucose (SMBG)
Article Information
Disclosure
Christopher G Parkin has received consulting
fees from CeQur, Dexcom, Inc., Insulet, Mannkind, Roche
Diabetes Care and Senseonics. Melissa Holloway is Chief
Adviser of INPUT Patient Advocacy and has received
consulting fees from Dexcom, Inc. and Ascensia Diabetes
Care UK Limited. Jeffrey Truesdell and Tomas C Walker
are employees of Dexcom, Inc. Dexcom, Inc., provided
funding for the development of this manuscript.
Correspondence
Christopher G Parkin,
CGParkin Communications, Inc., Boulder
City, NV, US. E: chris@cgparkin.org
Support
The publication of this article was
supported by Dexcom, Inc. The views and opinions
expressed are those of the authors and do not
necessarily reflect those of Dexcom, Inc.
Access
This article is published under the
Creative Commons Attribution Noncommercial License,
which permits any non-commercial use, distribution,
adaptation and reproduction provided the original
author(s) and source are given appropriate credit.
Received
2017-06-29T00:00:00
Further Resources
Trending Topic
Dipeptidyl peptidase-4 (DPP-4) is a ubiquitous, multifunctional, 766-amino acid, type 2 transmembrane glycoprotein, which participates in the regulation of metabolic functions, immune and inflammatory responses, cancer growth and cell adhesion.1 It has two forms: the first is a membrane-bound form, which is extensively expressed in the body, including the cells of the immune system, haematopoietic cells, […]
Metformin Metformin has been recommended as the first-line glucose-lowering agent for the management of type 2 diabetes (T2D) for several decades due to its efficacy and safety profile.1–3 In fact, metformin has been widely used as an insulin-sensitizing agent for ...
Welcome to the latest edition of touchREVIEWS in Endocrinology, which features a range of review, case report and original research articles that highlight some key developments in our understanding and management of endocrinological disease. We begin with a commentary from ...
Type 2 diabetes (T2D) continues to pose an ever-greater global health challenge, with 1.31 billion individuals predicted to be living with diabetes globally by 2050; the majority of whom will have T2D.1 Closely linked to T2D is metabolic dysfunction-associated steatotic ...
Gestational diabetes mellitus (GDM) is generally defined as “any degree of glucose tolerance with onset or first recognition during pregnancy”.1 It currently is one of the diseases with the highest morbidity among pregnant women.2 Determining its prevalence has been a ...
Despite the increasing body of knowledge of treatment strategies for diabetes, many patients with type 2 diabetes mellitus (T2DM) are still in a persistent state of poor glycaemia.1,2 In clinical practice, achieving optimal glycaemic targets is challenging; the reasons are ...
Type 2 diabetes (T2D) is one of the most common chronic noncommunicable diseases, its incidence is exponentially increasing and is one of the leading causes of morbidity and mortality worldwide.1 As of 2021, T2D ranked among the top causes of ...
Welcome to the latest edition of touchREVIEWS in Endocrinology. In this issue we feature a range of articles to keep you up to date with the latest discussions and developments in the field of medical endocrinology. We start with an ...
Type 1 diabetes mellitus (T1DM) is an autoimmune disease secondary to the destruction of the insulin-producing β cells of the islets of the pancreas. Environmental factors presumably trigger the disease in genetically susceptible individuals, leading to a lifetime dependency on exogenous ...
Highlights Enhanced external counterpulsation (EECP) is evaluated for glycaemic control in type 2 diabetes. Glycated haemoglobin reduction immediately after EECP therapy conclusion, after 2–4 weeks and after 7–12 weeks was -0.70%, 1.04% and 0.98%, respectively. EECP is associated with a significant lowering of blood pressure. ...
Diabetes mellitus (DM) is a group of metabolic disorders marked by elevated blood glucose. It has many subtypes, including type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes and neonatal diabetes; of these, T1DM and T2...
The incidence of diabetes has increased in recent years, and advances in technology have allowed for multiple ways to predict the outcomes of patients with diabetes, and have improved quality of life and lowered morbidity and mortality.1 For decades, glycated ...
Plan language summary Background The global COVID-19 pandemic resulted in an increased incidence of infection with Black fungus (Mucormycosis). However, the disease characteristics, chances of spread of infection and complications are not well known. Aim of the study We tried ...
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
